Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 6:11:1653-1661.
doi: 10.2147/DDDT.S109852. eCollection 2017.

CT-P13: design, development, and place in therapy

Tommaso Gabbani  1 , Simona Deiana  2 , Vito Annese  3
Affiliations
Review

CT-P13: design, development, and place in therapy

Tommaso Gabbani et al. Drug Des Devel Ther. .

Abstract

The introduction of biological agents has revolutionized the management of many life-threatening and debilitating immune-mediated diseases. Because of the high cost of biological drugs and their patent expiration, the market has opened to biosimilar agents, copy versions of the originators, which can lead to reduced health care expenditure and increase treatment access worldwide. CT-P13 is the first biosimilar of infliximab (IFX) and has been approved for the same indications as its originator drug. It obtained regulatory approval by the European Medicines Agency in September 2013 and by the US Food and Drug Administration in April 2016. The Phase I and Phase III clinical trials conducted in ankylosing spondylitis and rheumatoid arthritis have demonstrated pharmacokinetic and efficacy equivalence with comparable safety and immunogenicity to IFX. For these reasons, the use of CT-P13 has been extrapolated also to inflammatory bowel disease. There have been some initial concerns regarding the use of CT-P13 in inflammatory bowel disease patients, because of the lack of randomized controlled trials. However, emerging real-world data have further confirmed the comparability between CT-P13 and its reference product in terms of efficacy, safety, and immunogenicity, in patients naïve to the anti-tumor necrosis factor alpha agents and after switching from IFX, and will be summarized in this review.

Keywords: CT-P13; Crohn’s disease; biologic therapy; biosimilar; infliximab; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

    1. Solberg IC, Lygren I, Jahnsen J, et al. IBSEN Study Group Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) Scand J Gastroenterol. 2009;44:431–440. - PubMed
    1. Solberg I, Vatn M, Hoie O, et al. IBSEN Study Group Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438. - PubMed
    1. Danese S, Vuitton L, Peyrin-Biroulet L. Biological agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol. 2015;12:537–545. - PubMed
    1. Annese V, Duricova D, Gower-Rousseau C, Jess T, Langholz E. Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO. J Crohns Colitis. 2016;10(2):216–225. - PubMed
    1. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology – “O brave new world”. Nat Rev Rheumatol. 2012;8:430–436. - PubMed

MeSH terms